Advances in the use of somatostatins in the management of endocrine tumors

Current Opinion in Oncology

Volumn 8, Issue 1, 1996, Pages 44-48

  Chaudhry, Arvind ^a   Kvols, Larry ^a  

^a MALLINCKRODT PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; IODINE 123; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; PENTETATE INDIUM IN 111; PROTON PUMP INHIBITOR; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR;

ACROMEGALY; ANTINEOPLASTIC ACTIVITY; CARCINOID SYNDROME; CLINICAL TRIAL; ENDOCRINE TUMOR; GLUCAGONOMA; HUMAN; HYPOPHYSIS TUMOR; INSULINOMA; LUNG SMALL CELL CANCER; PRIMARY HYPERPARATHYROIDISM; PRIORITY JOURNAL; REVIEW; SCINTIGRAPHY; SUBCUTANEOUS DRUG ADMINISTRATION; THYROID MEDULLARY CARCINOMA; VERNER MORRISON SYNDROME; ZOLLINGER ELLISON SYNDROME;

EID: 0029974510     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199601000-00008     Document Type: Review

References (34)

1. Plewe G, Berger J, Krause U, Neufeld M, del Pozo E: Long acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet 1984, 11:782-784.
2. Lamberts SWS, Uitterlinden P, Verschow L, van Dongen KJ, del Pozo E: Long term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 1985, 313:1576-1579.
3. Evers BM, Parekh D, Townsend CM, Thompson JC: Somatostatin and analogues in the treatment of cancer: a review. Ann Surg 1991, 213:190.
4. Kutz K, Nuesch E, Rosenthal J: Pharmacokinetics of SMS 201-995 in healthy subjects. Scand J Gastroenterol 1986, 21(suppl 119):65-72.
5. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D, Lubbert H: Molecular pharmacology of somatostatin receptor subtypes. Ann N Y Acad Sci 1994, 733(suppl 1):138-146. This study describes somatostatin receptors and their cloning. It also discusses pharmacology and second-messenger coupling of somatostatin-receptor subtypes. It outlines the current understanding of somatostatin receptors and somatostatin analogues and their potential role in oncology.
6. Buscail L, Esteve JP, Prats H, Bayard F, Bell GI, Vaysse N, Susini C: Gastroenterology 1993, 104:A816.
7. Reubi JC, Kvols LK, Waser B, Nagorney D, Heitz PU, Charboneau JW, Reading CC, Moertel C: Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990, 50:5969-5977.
8. Kvols LK, Reubi JC, Horisberger U, Moertel CG, Rubin J, Charboneau JW: The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide. Yale J Biol Med 1992, 65:505-518.
9. Krenning EP, Bakker WH, Breeman WAP, Koper JW, Kooij PPM, Ausema L: Localization of endocrine-related tumors with radioiodinated analogue of somatostatin. Lancet 1989, i.242-244.
10. Kvols LK, Brown ML, O'Connor MK, Hung JC, Hayostek RJ, Reubi JC: Evaluation of radioiabelled somatostatin analogue (I-23 octreotide) in detection and localization of carcinoid and islet cell tumors. Radiology 1993, 187:129-133.
11. Janson ET, Westlin JE, Eriksson B, Ahlstrom H, Nilsson S, Öberg K: [111In-DTPA-D-Phel] octreotide scintigraphy in patients with carcinoid tumors: the predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994, 131(suppl 6):577-581. This study was performed to evaluate whether the presence or absence of somatostatin receptors in malignant carcinoid tumors detected by octreotide scintigraphy can be used to predict response to somatostatin analogue treatment. Thirty patients were investigated, 28 with midgut carcinoid tumors and two with foregut carcinoid tumors. Twenty-seven patients showed pathological uptake in tumor lesions at scintigraphy: 22 responded to somatostatin analogue treatment using octreotide, somatuline, or octastatin, whereas five patients did not respond. None of the three patients displaying negative scintigraphic investigations responded to treatment with somatostatin analogues. These results show a good correlation between the somatostatin receptor status and the patient's ability to respond to somatostatin analogue treatment (P=0.014). They concluded that somatostatin-receptor scintigraphy using octreotide can be used to select patients with malignant carcinoid tumors suitable for somatostatin analogue treatment and exclude those that will not benefit from such medication.
12. Moertel CG, Kvols LK, O'Connor MK, Rubin J: Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991, 68:227-232.
13. Kvols LK, Moertel CG, O'Connel MS, Schutt AJ, Rubin J, Hahn HG: Treatment of the malignant carcinoid syndrome: evaluation of a long acting somatostatin analogue. N Engl J Med 1986, 315:663-666.
14. Arnold R, Frank M, Kajdan U: Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues. Digestion 1994, 55(suppl 3):107-113. The place of the long-acting somatostatin analogue octreotide in the treatment of symptoms in patient with functional gastroenteropancreatic tumors and of growth in patients with metastatic disease is reviewed in this report. Currently, numerous studies indicate that octreotide is the therapeutic principle of first choice in the symptomatic treatment of patients with carcinoid syndrome, Verner-Morrison syndrome, and glucagonoma syndrome but not of insulinoma and gastrinoma patients. A beneficial effect on tumor growth has been demonstrated in 40% of patients with metastatic gastroenteropancreatic tumors with stabilization of the disease as the most favorable response.
15. Boden G, Ryan IG, Eisenschmid BL, Shelmet JJ, Own OL: Treatment of inoperative glucagonoma with long acting somatostatin analogue SMS 201-995. N Engl J Med 1986, 314:1686-1689.
16. Santangelo WC, O'Dorisio TH, Kim JG, Severino G, Krejs GJ: Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport. Ann Intern Med 1985, 103:363-367.
17. Ellison EL, O'Dorisio TM, Woltering EA, et al.: Suppression of gastrin and gastric acid secretion in the Zollinger Ellison syndrome by long acting somatostatin (SMS 201-995). Scand J Gastroenterol 1985, 21(suppl 119):206-211.
18. Maton PN, Gardner JD, Jensen RT: Use of long acting somatostatin analogue SMS 201-995 in patients with pancreatic islet cell tumors. Dig Dis Sci 1989, 34(suppl):285-291.
19. Scherubl H, Bäder M, Fett U, Hamm B, Schmidt-Gayk H, Koppenhagen K, Dop FJ, Riecken EO, Wiedenmann B: Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 1993, 105:1705-1709.
20. Nauck M, Stöckmann F, Creutzfeldt W: Evaluation of a euglycaemic clamp procedure as a diagnostic test in insulinoma patients. Eur J Clin Invest 1990, 20:15-28.
21. Lightman SL, Fox P, Dunne MJ: The effect of SMS 201-995, a long acting somatostatin analogue, on anterior pituitary function In healthy male volunteers. Scand J Gastroenterol 1986, 119(suppl):84-95.
22. Lucarotti ME, Hamilton JA, Farndon JR: Somatostatin and primary hyperparathyroidism. Br J Surg 1994, 81(suppl 8):1141-1143. This work examines the efficacy of the somatostatin analogue octreotide in the management of primary hyperparathyroidism. Twenty one patients were admitted before parathyroid surgery and were treated for 6 days with subcutaneous octreotide at 100 μ g twice daily. Fasting blood samples were taken for determination of serum levels of calcium and parathyroid hormone, and urinary calcium excretion was measured every 24 hours before and after treatment. A significant decrease in urinary calcium was demonstrated, but the reduction in serum calcium was not statistically significant and there was no change in serum parathyroid hormone concentration. Octreotide may provide therapy for patients with hyperparathyroidism and for those who have undergone successful neck exploration or who are unfit for operation. It may also ameliorate hypercalciuria and reduce stone formation.
23. 111In-octreotide was also effective in cancer patients with low levels of NSE.
24. Cotto C, Quiox E, Thomas F, Henane S, Trillet-Lenoir V: Phase I study of the somatostatin analogue somatuline in refractory small cell lung carcinoma [letter]. Ann Oncol 1994, 5(suppl 3):290-291.
25. Nakanishi Y, Mulshine JL, Kasprisz PG, Natale RB, Maneckjee R, Avis I, Treston AM, Gazdar AF, Minna JD, Cuttitta F: Insulin like growth factor-1 can mediate autocrine proliferation of human small cell lung cancers in vitro. J Clin Invest 1988, 82:354-359.
26. Frank Raue K, Raue F, Ziegler R: Therapy of metastatic medullary thyroid gland carcinoma with the somatostatin analogue octreotide. Med Klin 1995, 90(suppl 2):63-66. In seven patients with metastasizing medullary thyroid carcinoma, the antisecretory and antiproliferative effects of somatostatin were evaluated in a prospective study. Treatment with octreotide in daily doses between 100 and 1000 μ g resulted in a remission lasting up to 12 months in two of seven patients. A decrease of tumor marker levels was observed in two patients; improvement of diarrhea and a remission of a lymph node metastasis in one of these. This minor therapeutic effect may be due to the relatively low density of receptors or with a low affinity of the receptors expressed in medullary thyroid carcinoma to octreotide.
27. Ezzat S, Ren SG, Braunstein GD, Melmed S: Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. J Clin Endocrinol Metab 1992, 75:1459-1463.
28. Woltering EA, Barrie R, O'Dorisio TM, Arce D, Ure T, Cramer A, Holmes D, Robertson J, Fassler J: Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane. J Surg Res 1991, 50:251-254.
29. Mascardo RN, Sherline P: Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology 1982, 111:1394-1396.
30. Setyono HB, Henkelman MS, Foekens JA, Klijn GM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 1987, 47:1566-1570.
31. Liebow C, Hierowski M, Sapin K: Hormonal control of pancreatic growth cancer. Pancreas 1986, 1:44-48.
32. Hofland J, van Koetsveld PM, Wouters N, Waaijers M, Reubi JC, Lamberts SW: Dissociation of antiproliferative and antihormonal effects of the somatostatin analogue octreotide on 7315b pituitary tumor cells. Endocrinology 1992, 131:571-577.
33. Gordon PH: NIH conference: somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone secreting tumors of the pituitary and gastrointestinal tract and nonneoplastic diseases of the gut. Ann Intern Med 1989, 110:35-50.
34. Saltz L, Trochanowski B, Buckley M, Hefferman B, Niedzwiecki D, Tao Y, Kelsen D: Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer 1993, 72:244-248.